Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChimeriVax-JE vs JE-VAX in Japanese Encephalitis
NCT00314145Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2005
- Primary completion
- Jun 2006
- Modality
- Live Attenuated Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of japanese encephalitis chimeric virus vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Sanofi. Primary endpoints: Number of Participants With Japanese Encephalitis (Homologous Virus) Seroconversion at Day 60 and Number of Participants Reporting Treatment Emergent Local Adverse Events and Treatment Emergent Systemic Reactions. Started Nov 2005; status: completed.
02
Drugs
japanese encephalitis chimeric virus vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT00314145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00314145.